Phase 2 N=79 Minocycline Study in Pancreatic Cancer Patients
Pancreatic Cancer
Primary: Average Area Under the Curve (AUC) of Apriori Selected MDASI Symptoms — 51.5; 30.6; 36.2 Units on a scale *days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=92 Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients
Neuromuscular Blockade
Primary: Number of Hypoxic Episodes — 1; 0 episode(s)
N/A N=15 Mucinex® for Treatment of Filamentary Keratitis
Filamentary Keratitis
Primary: Change in Number of Corneal Filaments — 5.8; 2.1 corneal filaments — p=<0.04
N/A N=10 FDG PET/MRI Evaluation of Facet Joint Pain
Low Back Pain
Primary: Facet Joint High Grade FDG Activity Concordance to Pain — 0.10 concordance correlation coefficient
N/A N=10 Microbiome and Metagenome in Percutaneous Osseointegrated Prostheses (MMPOP)
Transfemoral Amputation
Primary: Bacterial Community Types as Determined by Percentage RNA Sequence Reads — 3.4; 4.6; 4.7; 8.7 Percentage RNA sequence reads — p=<0.05
N/A N=21 Activating Behavior for Lasting Engagement After Stroke
Stroke · Physical Activity · Sedentary Lifestyle
Primary: Change in Daily Sedentary Time Accumulated in Bouts Greater Than or Equal to 30 Minutes — 54.95 minutes
N/A N=7 Upper Extremity Rehabilitation With the BURT Robotic Arm
Stroke · Hemiparesis
Primary: Changes From Baseline in Fugl-Meyer Upper Extremity Scores — 3.50 score on a scale
Phase 3 N=3,706 Providing Free Nicotine Patches to Quitline Smokers
Smoking Cessation
Primary: Number of Participants With Six Months Prolonged Abstinence — 61; 76; 151 Participants
Phase 3 N=380 SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis
Spondyloarthritis
Primary: Percentage of Participants With a Spinal Pain Numerical Rating Scale (NRS) Score Below 4 at Week 8 (Treatment Period 1) — 91; 19; 188; 73 Participants — p=0.0264
Phase 4 N=20 DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence
Adherence, Medication · Risk Behavior · Pre-Exposure Prophylaxis
Primary: DOT Diary Mobile App Acceptability — 79.8 Score on scale
Phase 2 N=44 High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
Melanoma
Primary: Objective Response Rate — 25 percentage of participants
N/A N=2,707 Walk On! Physical Activity Coaching
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Number of Participants With All-cause Hospitalizations, Emergency Department (ED) Visits, Observation Stays, and Deaths — 864; 883 Participants — p=0.33
N/A N=25 Sleep Timing and Insulin Resistance in Adolescents With Obesity
Obesity
Primary: Dim Light Melatonin Onset and Offset — 21.33; 8.32 decimal hours
Phase 2 N=10 Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia
Primary: Occurrence of a Dose-Limiting Toxicity (Phase 1) — 0; 1; 4; 5 Participants
Phase 2 N=70 Safety and Efficacy of Nemolizumab in PN
Prurigo Nodularis
Primary: Percent Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale (NRS) Score at Week 4 Using Last Observation Carried Forward (LOCF) Approach…